Moreover, the 36-month beta value for RLAY is 1.60. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RLAY is 123.36M and currently, short sellers hold a 9.79% of that float. On January 01, 2025, RLAY’s average trading volume was 1.92M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RLAY) stock’s latest price update
Relay Therapeutics Inc (NASDAQ: RLAY) has seen a decline in its stock price by -1.44 in relation to its previous close of 4.18. However, the company has experienced a -5.07% decline in its stock price over the last five trading sessions. zacks.com reported 2024-12-20 that Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
RLAY’s Market Performance
Relay Therapeutics Inc (RLAY) has experienced a -5.07% fall in stock performance for the past week, with a -12.34% drop in the past month, and a -37.10% drop in the past quarter. The volatility ratio for the week is 5.75%, and the volatility levels for the past 30 days are at 6.78% for RLAY. The simple moving average for the past 20 days is -7.32% for RLAY’s stock, with a -37.93% simple moving average for the past 200 days.
Analysts’ Opinion of RLAY
Many brokerage firms have already submitted their reports for RLAY stocks, with Jefferies repeating the rating for RLAY by listing it as a “Buy.” The predicted price for RLAY in the upcoming period, according to Jefferies is $16 based on the research report published on September 10, 2024 of the previous year 2024.
Goldman, on the other hand, stated in their research note that they expect to see RLAY reach a price target of $20. The rating they have provided for RLAY stocks is “Buy” according to the report published on September 10th, 2024.
RLAY Trading at -19.58% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.06% of loss for the given period.
Volatility was left at 6.78%, however, over the last 30 days, the volatility rate increased by 5.75%, as shares sank -11.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.78% lower at present.
During the last 5 trading sessions, RLAY fell by -5.07%, which changed the moving average for the period of 200-days by -48.18% in comparison to the 20-day moving average, which settled at $4.45. In addition, Relay Therapeutics Inc saw -62.58% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Adams Brian, who sale 299 shares at the price of $4.38 back on Dec 27 ’24. After this action, Adams Brian now owns 321,608 shares of Relay Therapeutics Inc, valued at $1,310 using the latest closing price.
Bergstrom Donald A, the President, R&D of Relay Therapeutics Inc, sale 657 shares at $4.38 during a trade that took place back on Dec 27 ’24, which means that Bergstrom Donald A is holding 520,088 shares at $2,878 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -39.27 for the present operating margin
- 0.59 for the gross margin
The net margin for Relay Therapeutics Inc stands at -34.5. The total capital return value is set at -0.44. Equity return is now at value -42.69, with -37.58 for asset returns.
Currently, EBITDA for the company is -374.15 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 58.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.42.
Conclusion
To wrap up, the performance of Relay Therapeutics Inc (RLAY) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
